Pfizer and BioNTech Begin Trials for New Omicron-Targeted Vaccine

By Korir Isaac / Published January 26, 2022 | 11:31 am




KEY POINTS

The companies plan to test the immune response generated by the Omicron-based vaccine both as a three-shot regimen in unvaccinated people and as a booster shot for people who already received two doses of their original vaccine.


Covid-19 Vaccine

KEY TAKEAWAYS


The companies plan to study the safety and tolerability of the shots in the more than 1,400 people who will be enrolled in the trial.


Pfizer and BioNTech have begun a clinical trial to test a new version of a vaccine specifically designed to target the COVID-19 Omicron variant, which has eluded some of the protection provided by the original two-dose vaccine regimen.

The companies plan to test the immune response generated by the Omicron-based vaccine both as a three-shot regimen in unvaccinated people and as a booster shot for people who already received two doses of their original vaccine.

They are also testing a fourth dose of the current vaccine against a fourth dose of the Omicron-based vaccine in people who received their third dose of the Pfizer/BioNTech vaccine three to six months earlier.

The companies plan to study the safety and tolerability of the shots in the more than 1,400 people who will be enrolled in the trial.

“While current research and real-world data show that boosters continue to provide a high level of protection against severe disease and hospitalization with Omicron, we recognize the need to be prepared in the event this protection wanes over time and to potentially help address Omicron and new variants in the future,” Pfizer’s head of vaccine research and development, Kathrin Jansen, said in a statement.

ALSO READ: West Kenya Applies for A Joinder In Mumias Sugar Proceedings

Pfizer has said that a two-dose regimen of the original vaccine may not be sufficient to protect against infection from the Omicron variant, and that protection against hospitalizations and deaths may be waning.

Still, reports indicate that the third dose of an mRNA like the Pfizer/BioNTech vaccine provides 90 percent protection against hospitalization due to COVID-19.

Some countries have already started offering additional booster doses, but a recent study from Israel showed that while the fourth dose of an mRNA vaccine boosted antibodies, the level was not high enough to prevent infection by the Omicron variant.

BioNTech Chief Executive Ugur Sahin noted in November that regulators would not likely require testing of an Omicron-based vaccine on humans because it and Pfizer had already created versions of their established vaccine. Their earlier versions targeted the Alpha and Delta variants, and clinical trials are still continuing.

However, the debate appears to have shifted as the European Medicines Agency (EMA) said in a statement on Friday that international regulators now preferred clinical studies to be carried out before approval of a new vaccine.

These studies should show that neutralizing antibodies in the blood of participants are superior to those elicited by current vaccines. Another desired feature of an upgraded vaccine would be for it to also protect against other variants of concern, the EMA said.

The Omicron variant has replaced the Delta variant as the dominant lineage in many parts of the world and Omicron itself is now splitting into different subforms, one of which, BA2, is causing particular concern.

Meanwhile, the number of Covid-19 cases in Kenya continues with 185 new confirmed cases reported in January 25th from a sample size of 5,515 people. The positivity rate stands at 3.4 percent.




About Korir Isaac

A creative, tenacious, and passionate journalist with impeccable ethics and a nose for anticipated and spontaneous news. He may not say it, but he sure can make one hell of a story.

View other posts by Korir Isaac


More Articles From This Author








Trending Stories










Other Related Articles










SOKO DIRECTORY & FINANCIAL GUIDE



ARCHIVES

2022
  • January 2022 (294)
  • February 2022 (329)
  • March 2022 (361)
  • April 2022 (294)
  • May 2022 (206)
  • 2021
  • January 2021 (182)
  • February 2021 (227)
  • March 2021 (325)
  • April 2021 (259)
  • May 2021 (285)
  • June 2021 (273)
  • July 2021 (277)
  • August 2021 (232)
  • September 2021 (271)
  • October 2021 (305)
  • November 2021 (364)
  • December 2021 (250)
  • 2020
  • January 2020 (272)
  • February 2020 (310)
  • March 2020 (390)
  • April 2020 (321)
  • May 2020 (335)
  • June 2020 (327)
  • July 2020 (333)
  • August 2020 (276)
  • September 2020 (214)
  • October 2020 (233)
  • November 2020 (242)
  • December 2020 (187)
  • 2019
  • January 2019 (251)
  • February 2019 (215)
  • March 2019 (283)
  • April 2019 (254)
  • May 2019 (269)
  • June 2019 (250)
  • July 2019 (337)
  • August 2019 (293)
  • September 2019 (306)
  • October 2019 (313)
  • November 2019 (362)
  • December 2019 (318)
  • 2018
  • January 2018 (291)
  • February 2018 (213)
  • March 2018 (275)
  • April 2018 (223)
  • May 2018 (235)
  • June 2018 (176)
  • July 2018 (256)
  • August 2018 (247)
  • September 2018 (255)
  • October 2018 (282)
  • November 2018 (282)
  • December 2018 (184)
  • 2017
  • January 2017 (183)
  • February 2017 (194)
  • March 2017 (207)
  • April 2017 (104)
  • May 2017 (169)
  • June 2017 (205)
  • July 2017 (190)
  • August 2017 (195)
  • September 2017 (186)
  • October 2017 (235)
  • November 2017 (253)
  • December 2017 (266)
  • 2016
  • January 2016 (164)
  • February 2016 (165)
  • March 2016 (189)
  • April 2016 (143)
  • May 2016 (245)
  • June 2016 (182)
  • July 2016 (271)
  • August 2016 (247)
  • September 2016 (233)
  • October 2016 (191)
  • November 2016 (243)
  • December 2016 (153)
  • 2015
  • January 2015 (1)
  • February 2015 (4)
  • March 2015 (164)
  • April 2015 (107)
  • May 2015 (116)
  • June 2015 (119)
  • July 2015 (145)
  • August 2015 (157)
  • September 2015 (186)
  • October 2015 (169)
  • November 2015 (173)
  • December 2015 (205)
  • 2014
  • March 2014 (2)
  • 2013
  • March 2013 (10)
  • June 2013 (1)
  • 2012
  • March 2012 (7)
  • April 2012 (15)
  • May 2012 (1)
  • July 2012 (1)
  • August 2012 (4)
  • October 2012 (2)
  • November 2012 (2)
  • December 2012 (1)
  • 2011
    2010
    2009
    2008
    2007
    2006
    2005
    2004
    2003
    2002
    2001
    2000
    1999
    1998
    1997
    1996
    1995
    1994
    1993
    1992
    1991
    1990
    1989
    1988
    1987
    1986
    1985
    1984
    1983
    1982
    1981
    1980
    1979
    1978
    1977
    1976
    1975
    1974
    1973
    1972
    1971
    1970
    1969
    1968
    1967
    1966
    1965
    1964
    1963
    1962
    1961
    1960
    1959
    1958
    1957
    1956
    1955
    1954
    1953
    1952
    1951
    1950